Andreas Schulze-Bonhage is an expert in Neurology at University of Freiburg (Germany). As of October 2026, ScienceLeadR ranks Andreas Schulze-Bonhage in the top 1% of experts worldwide for Seizures and Epilepsy. Andreas Schulze-Bonhage has authored 578 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 2 of them ongoing. SLR score: 1,838 (community average: 125). How the SLR is computed.

LeadR Profile

Andreas Schulze-Bonhage University of Freiburg Germany
1 838 ScienceLeadR Reputation 1838
Network Map

Neurology

Subspecialties: Neurosurgery - Psychology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

Andreas Schulze-Bonhage is Professor of Neurology and Clinical Neurophysiology and Head of the European Reference Epilepsy Center at the University Medical Center Freiburg in Germany. The Freiburg epilepsy center has Germany`s largest university-based epilepsy surgery program for children and adults and offers comprehensive epilepsy care for rare and complex epilepsies.

Andreas Schulze-Bonhage has served as the president of the German Society of Epileptology 2019-2021, is member of the German Societies of Epileptology, Neurology, and Clinical Neurophysiology as well as of the American Epilepsy Society. He has received the Epilepsy Ambassador award by the International Leage Against Epilepsy in 2025.

Clinical research interests include advanced EEG diagnostics, long-term monitoring of epilepsy including wearables and subcutaneous EEG, neurophysiology of cognition, and emerging pharmacological and non-pharmacological treatment options in epilepsy including new approaches of neuromodulation and epilepsy surgery.

Andreas Schulze-Bonhage has served as PI (in part as national lead) in >50 pharmacological and device trials, has published > 495 peer-reviewed papers (>34.000 citations, h-index 90, Google Scholar) and has obtained research support from the BMBF, EU, NIH, German Ministry of Science, Epilepsy Foundation as well as from pharmaceutical and device companies.

Organizations

Career arc: 1998 - 2026

Source: PubMed

University of Freiburg

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 578

Citations

Citations: 25 989 1st author: 50 Last author: 154 Unique author: 34


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Navigation strategies predict spatial memory and hippocampal recruitment.
PMID 42789386 — hippocampus, spatial memory, biological science disciplines, spatial learning, memory
Cell Rep20260
Blue-Tinted Glasses in Photosensitive Epilepsy in Road Traffic: Protection or Risk?
PMID 42708454 — epilepsy, eyeglasses
Dtsch Arztebl Int20260
DECREASE study: A European pool-analysis of patients with significant reductions in concomitant antiseizure medications in cenobamate Early Access Programs.
PMID 42625556 — epilepsy, pharmaceutical preparations, seizures, therapeutics
Epilepsia Open20260
Direct cortical stimulation-evoked symptoms in the human temporal pole: A systematic review.
PMID 42622362 — epilepsy, epilepsies, partial, signs and symptoms, seizures, temporal lobe
Epileptic Disord20260
Epileptic arousals: A neglected clinical entity.
PMID 42615224 — autonomic nervous system, epilepsy, heart rate, epilepsies, partial, sleep, electroencephalography, arousal, seizures, electrocorticography, electrocardiography
Epilepsia20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

N/A 5
Phase 2 2

By status:

Completed 3
Active not recruiting 2
Enrolling by invitation 1
Recruiting 1

By type:

Interventional 4
Observational 3

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 7

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
REACH RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization
NCT06922175 — epilepsy, retrospective studies, seizures
N/ARecruiting2024
5 SENSE Score Validation Study
NCT06138808 — drug resistant epilepsy, epilepsy, pharmaceutical preparations, electroencephalography, seizures
N/AEnrolling by invitation2024

LeadR Networks

Main global connection map